Neonatal jaundice, unspecified. Neonatal jaundice, unspecified
Conditions
Interventions
Intervention group: In the intervention group, newborns receive oral silymarin drops from the first day of birth at a dose of 4 mg per kilogram of body weight every 12 hours. The silymarin, with a con
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Days to 10 Days
Inclusion criteria
Inclusion criteria: Full-term newborns who are negative for the Coombs test at birth. Healthy full-term newborns who do not require phototherapy. Newborns whose bilirubin levels are not in the range requiring blood exchange. Newborns with no history of the mother taking any kind of medication during pregnancy.
Exclusion criteria
Exclusion criteria: Newborns with RH incompatibility who are positive for the Coombs test. Newborns with an increase in bilirubin to the level requiring blood exchange. Newborns requiring phototherapy on the first day of birth. Deterioration in the newborn's condition during hospitalizationwith dehydration, sepsis, pneumonia, anemia, severe weight loss, hypoglycemia, renal failure, or heart failure. Newborns with a history of the mother taking any kind of medication during pregnancy or mothers who have received phenobarbital. Newborns who experience severe drug reactions following the use of silymarin. Parents' refusal to continue treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcutaneous bilirubin level. Timepoint: 24,48 and 72 hours after birth. Method of measurement: Bilichek device. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamidreza Goldouzi
Mashhad University of Medical Sciences
Outcome results
None listed